3 results
Approved WMOCompleted
To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.
Approved WMOCompleted
PrimaryTo evaluate confirmed ORR of Trastuzumab deruxtecan in human epidermal growth factor receptor 2- (HER2-) mutated NSCLC subjects treated at 5.4 and 6.4 mg/kg doses.Secundary- To evaluate the clinical efficacy of Trastuzumab deruxtecan at 5.4…
Approved WMOCompleted
primary objective:To evaluate the effect of individualised FE 999049 treatment on ovarian response in a long GnRH agonist protocol versus a GnRH antagonist protocolSecondary objectives:* To evaluate the effect of individualised FE 999049 treatment…